Therapeutic PEG-ceramide nanomicelles synergize with salinomycin to target both liver cancer cells and cancer stem cells

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 303(5665), 1818–1822 (2004).
  Medline CASGoogle Scholar
• 2 Banzato A, Bobisse S, Rondina M et al. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin. Cancer. Res. 14(11), 3598–3606 (2008).
  Medline CASGoogle Scholar
• 3 Chung JE, Tan S, Gao SJ et al. Self-assembled micellar nanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy. Nat. Nanotechnol. 9(11), 907–912 (2014). •• An excellent article suggesting that therapeutic drug carriers can solve the issue of the use of high quantities of carriers.
  Medline CASGoogle Scholar
• 4 Saddoughi SA, Ogretmen B. Diverse functions of ceramide in cancer cell death and proliferation. Adv. Cancer Res. 117, 37–58 (2013).
  Medline CASGoogle Scholar
• 5 Jayadev S, Liu B, Bielawska AE et al. Role for ceramide in cell cycle arrest. J. Biol. Chem. 270(5), 2047–2052 (1995).
  Medline CASGoogle Scholar
• 6 Kitatani K, Usui T, Sriraman SK et al. Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid. Oncogene 35(21), 2801–2812 (2016).
  Medline CASGoogle Scholar
• 7 Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science 274(5294), 1855–1859 (1996).
  Medline CASGoogle Scholar
• 8 Kitatani K, Sheldon K, Anelli V et al. Acid beta-glucosidase 1 counteracts p38delta-dependent induction of interleukin-6: possible role for ceramide as an anti-inflammatory lipid. J. Biol. Chem. 284(19), 12979–12988 (2009).
  Medline CASGoogle Scholar
• 9 Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism-a strategy for overcoming drug resistance. J. Natl Cancer Inst. 93(5), 347–357 (2001).
  Medline CASGoogle Scholar
• 10 Rath G, Schneider C, Langlois B et al. De novo ceramide synthesis is responsible for the anti-tumor properties of camptothecin and doxorubicin in follicular thyroid carcinoma. Int. J. Biochem. Cell. Biol. 41(5), 1165–1172 (2009).
  Medline CASGoogle Scholar
• 11 Li F, Zhang N. Ceramide: therapeutic potential in combination therapy for cancer treatment. Curr. Drug. Metab. 17(1), 37–51 (2015).
  Medline CASGoogle Scholar
• 12 Feng LX, Li M, Liu YJ et al. Synergistic enhancement of cancer therapy using a combination of ceramide and docetaxel. Int. J. Mol. Sci. 15(3), 4201–4220 (2014).
  MedlineGoogle Scholar
• 13 Su X, Song H, Niu F et al. Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance. Nanomedicine (Lond.) 10(13), 2033–2050 (2015).
  CASGoogle Scholar
• 14 Han L, Miyasaka K, Terasaki O et al. Evolution of packing parameters in the structural changes of silica mesoporous crystals: cage-type, 2D cylindrical, bicontinuous diamond and gyroid, and lamellar. J. Am. Chem. Soc. 133(30), 11524–11533 (2011).
  Medline CASGoogle Scholar
• 15 Khazanov E, Priev A, Shillemans JP et al. Physicochemical and biological characterization of ceramide containing liposomes: paving the way to ceramide therapeutic application. Langmuir 24(13), 6965–6980 (2008).
  Medline CASGoogle Scholar
• 16 Mao X, Liu J, Gong Z et al. iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells. Nanomedicine (Lond.) 10(17), 2677–2695 (2015).
  CASGoogle Scholar
• 17 Ashok B, Arleth L, Hjelm RP et al. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J. Pharm. Sci. 93(10), 2476–2487 (2004).
  Medline CASGoogle Scholar
• 18 Zhao BJ, Ke XY, Huang Y et al. The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats. J. Drug. Target. 19(5), 382–390 (2011).
  Medline CASGoogle Scholar
• 19 Wang AT, Liang DS, Liu YJ et al. Roles of ligand and TPGS of micelles in regulating internalization, penetration and accumulation against sensitive or resistant tumor and therapy for multidrug resistant tumors. Biomaterials 53, 160–172 (2015).
  Medline CASGoogle Scholar
• 20 Xie F, Zhang S, Liu J et al. Codelivery of salinomycin and chloroquine by liposomes enables synergistic antitumor activity in vitro. Nanomedicine (Lond.) 11(14), 1831–1846 (2016).
  CASGoogle Scholar
• 21 Gong Z, Chen D, Xie F et al. Codelivery of salinomycin and doxorubicin using nanoliposomes for targeting both liver cancer cells and cancer stem cells. Nanomedicine (Lond.) 11(19), 2565–2579 (2016).
  CASGoogle Scholar
• 22 Naujokat C, Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. J. Biomed. Biotechnol. 2012, 950658 (2012). •• An excellent article elucidating salinomycin is a potent drug in killing cancer stem cells (CSCs).
  MedlineGoogle Scholar
• 23 Boehmerle W, Endres M. Salinomycin induces calpain and cytochrome c-mediated neuronal cell death. Cell. Death Dis. 2, e168 (2011).
  Medline CASGoogle Scholar
• 24 Liboiron BD, Mayer LD. Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy. Ther. Deliv. 5(2), 149–171 (2014).
  Medline CASGoogle Scholar
• 25 Song H, Su X, Yang K et al. CD20 antibody-conjugated immunoliposomes for targeted chemotherapy of melanoma cancer initiating cells. J. Biomed. Nanotechnol. 11(11), 1927–1946 (2015).
  Medline CASGoogle Scholar
• 26 Yang K, Lu Y, Xie F et al. Cationic liposomes induce cell necrosis through lysosomal dysfunction and late-stage autophagic flux inhibition. Nanomedicine (Lond.) 11(23), 3117–3137 (2016).
  CASGoogle Scholar
• 27 Gao J, Chen H, Yu Y et al. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA. Biomaterials 34(38), 10084–10098 (2013).
  Medline CASGoogle Scholar
• 28 Ren J, Shen S, Wang D et al. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 33(11), 3324–3333 (2012).
  Medline CASGoogle Scholar
• 29 Chou TC, Talaly P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J. Biol. Chem. 252(18), 6438–6442 (1977).
  Medline CASGoogle Scholar
• 30 Huang J, Zhang H, Yu Y et al. Biodegradable self-assembled nanoparticles of poly(D,L-lactide-co-glycolide)/hyaluronic acid block copolymers for target delivery of docetaxel to breast cancer. Biomaterials 35(1), 550–566 (2014).
  MedlineGoogle Scholar
• 31 Li W, Li J, Gao J et al. The fine-tuning of thermosensitive and degradable polymer micelles for enhancing intracellular uptake and drug release in tumors. Biomaterials 32(15), 3832–3844 (2011).
  Medline CASGoogle Scholar
• 32 Tong Z, Luo W, Wang Y et al. Tumor tissue-derived formaldehyde and acidic microenvironment synergistically induce bone cancer pain. PLoS ONE 5(4), e10234 (2010).
  MedlineGoogle Scholar
• 33 Wei T, Liu J, Ma H et al. Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo. Nano Lett. 13(6), 2528–2534 (2013).
  MedlineGoogle Scholar
• 34 Gupta PB, Onder TT, Jiang G et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138(4), 645–659 (2009). •• An excellent article elucidating salinomycin is a potent drug in killing CSCs.
  Medline CASGoogle Scholar
• 35 Lu W, Wan J, She Z et al. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J. Control. Release 118(1), 38–53 (2007).
  Medline CASGoogle Scholar
• 36 Musacchio T, Torchilin VP. Recent developments in lipid-based pharmaceutical nanocarriers. Front. Biosci. 16, 1388–1412 (2011).
  CASGoogle Scholar
• 37 Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2(5), 347–360 (2003).
  Medline CASGoogle Scholar
• 38 Jia T, Sun Z, Lu Y et al. A dual brain-targeting curcumin-loaded polymersomes ameliorated cognitive dysfunction in intrahippocampal amyloid-β1–42-injected mice. Int. J. Nanomedicine 11, 3765–3775 (2016).
  Medline CASGoogle Scholar
• 39 Yin C, Lin Y, Zhang X et al. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology 48(5), 1528–1539 (2008).
  Medline CASGoogle Scholar
• 40 Yin C, Wang PQ, Xu WP et al. Hepatocyte nuclear factor-4α reverses malignancy of hepatocellular carcinoma through regulating miR-134 in the DLK1-DIO3 region. Hepatology 58(6), 1964–1976 (2013).
  Medline CASGoogle Scholar
• 41 Chiba T, Kita K, Zheng YW et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell like properties. Hepatology 44(1), 240–251 (2006).
  Medline CASGoogle Scholar
• 42 Yin C, Xie WF. Differentiation therapy with transcription factors might present as an ideal strategy for the treatment of cancer. Hepatology 50(6), 2046–2047 (2009).
  MedlineGoogle Scholar
• 43 Yin C, Xie WF. Hepatocellular carcinoma: basic and transitional research. Gastrointest. Tumors 1(2), 76–83 (2014).
  Medline CASGoogle Scholar
• 44 Zeng X, Lin Y, Yin C et al. Recombinant adenovirus carrying the hepatocyte nuclear factor-1α gene inhibits hepatocellular carcinoma xenograft growth in mice. Hepatology 54(6), 2036–2047 (2011).
  Medline CASGoogle Scholar
• 45 Chaffer CL, Brueckmann I, Scheel C et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. USA 108(19), 7950–7955 (2011). •• An excellent article elucidating non-CSCs in the tumor can spontaneously and stochastically turn into CSCs de novo.
  Medline CASGoogle Scholar
• 46 Xie FY, Xu WH, Yin C et al. Nanomedicine strategies for sustained, controlled, and targeted treatment of cancer stem cells of the digestive system. World J. Gastrointest. Oncol. 8(10), 735–744 (2016).
  MedlineGoogle Scholar
• 47 Gao J, Feng SS, Guo Y. Nanomedicine for treatment of cancer stem cells. Nanomedicine (Lond.) 9(2), 181–184 (2014).
  CASGoogle Scholar
• 48 Abraham SA, McKenzie C, Masin D et al. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin. Cancer. Res. 10(2), 728–738 (2004).
  Medline CASGoogle Scholar
• 49 Zucker D, Barenholz Y. Optimization of vincristine-topotecan combination-paving the way for improved chemotherapy regimens by nanoliposomes. J. Control. Release 146(3), 326–333 (2010).
  Medline CASGoogle Scholar